Seagen Inc.
Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics is advancing a robust pipeline of novel therapies for both solid tumors and blood-related cancers designed to address significant unmet medical needs for patients.